BiondVax Pharmaceuticals Ltd. (Form: 6-K, Received: 06/23/2021 09:40:49)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of June 2021

Commission File Number: 001-37353

BIONDVAX PHARMACEUTICALS LTD.

(Translation of registrant’s name into English)

Jerusalem BioPark, 2nd Floor

Hadassah Ein Kerem Campus

Jerusalem, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

On June 23, 2021, BiondVax Pharmaceuticals Ltd. issued a press release announcing first quarter 2021 financial results.

Exhibit Index

Exhibit No.		Description
99.1		Press Release dated June 23, 2021
99.2		BiondVax Pharmaceuticals Ltd. unaudited financial statements for the period ending March 31, 2021

This Report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Registration No. 333-240189) and its Registration Statement on Form S-8 (Registration No. 333-239344).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BiondVax Pharmaceuticals Ltd.

Date: June 23, 2021	By:	/s/ Amir Reichman
		Amir Reichman
		Chief Executive Officer

Exhibit 99.1

BiondVax Announces First Quarter 2021 Financial Results and Provides Business Update

Jerusalem, Israel – June 23, 2021 – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today published its first quarter financial results for the quarter ended March 31, 2021. A summary is included in the tables below.

First Quarter 2021 Financial Summary

Results are in New Israel Shekels (NIS) and convenience translation to $US is provided using the exchange rate of 3.334 (NIS/$US), the rate as of the close of business on March 31, 2020.

●

Total operating expenses were NIS 6.7 million ($2.0 million) compared with NIS 20.0 million for the first quarter of 2020

●

Out of the operating expenses, first quarter R&D expenses amounted to NIS 2.75 million ($0.83 million) compared with NIS 19.0 million for the first quarter of 2020

The decrease in total operating expenses, including the R&D expenses, compared to the first quarter of 2020 was primarily attributable to expenses related to a Phase 3 clinical trial and related operations at our manufacturing facility. As previously reported, the trial concluded in Q4 2020. As of March 31, 2021, BiondVax had cash and cash equivalents of NIS 48.6 million ($14.6 million) as compared to NIS 9.4 million as of December 31, 2020. The increase was primarily attributable to a follow-on offering on Nasdaq conducted by the Company in February 2021, providing net proceeds of approximately $12.8 million after fees and underwriter discounts. As previously reported, as of May 12, 2021, the Company had cash and cash equivalents of NIS 46 million (approximately $14 million).

Q1 Business Highlights

●

New CEO appointed: Mr. Amir Reichman, a GSK veteran, began serving as BiondVax’s CEO

●

BiondVax’s new mission announced: To develop, manufacture and ultimately commercialize products for the prevention and treatment of infectious diseases and related illnesses

●

Reviewing opportunities: Continuing to analyze potential opportunities towards the creation of a diversified pipeline of products and platforms

●

Successful financing: Follow-on offering on Nasdaq providing net proceeds of approximately $12.8 million after fees and underwriter discounts

●

Investor Relations: Engaged Edison Group to support our upcoming global investor relations outreach activities

About BiondVax

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses. The Company had been developing M-001, a novel influenza vaccine candidate that was designed to provide multi-strain and multi-season protection against current and future seasonal and pandemic influenza. In seven Phase 1/2 and Phase 2 clinical trials designed to test for immunogenicity, the Company was able to demonstrate M-001 was effective in stimulating an immune response to a broad range of influenza virus strains. In October 2020, the Company completed a Phase 3 clinical trial of M-001 which failed to meet the trial’s primary and secondary efficacy endpoints. The Company is now pursuing opportunities in the infectious disease space towards development of a pipeline of diversified products and platforms.

Contact Details

Company: Joshua E. Phillipson | +972 8 930 2529 | j.phillipson@biondvax.com

Investor Relations: Kenny Green | +1 646 201 9246 | kgreen@edisongroup.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements, including statements regarding future business strategies that BiondVax may explore. These forward-looking statements reflect management’s current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, the risk that BiondVax may not be able to secure additional capital on attractive terms, if at all; the risk that the European Investment Bank may accelerate the loans under its finance contract with BiondVax; the risk that BiondVax may not execute a strategic alternative to M-001 or implement a strategy that will diversify BiondVax’s risk, and, if executed, may not be successful; risks relating to the COVID-19 (coronavirus) pandemic; BiondVax’s ability to acquire rights to additional product opportunities; BiondVax’s ability to enter into collaborations on terms acceptable to BiondVax or at all; timing of receipt of regulatory approval of BiondVax’s manufacturing facility in Jerusalem, if at all or when required; the risk that the manufacturing facility will not be able to be used for a wide variety of applications and other vaccine and treatment technologies, and the risk that drug development involves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission on May 13, 2021. BiondVax undertakes no obligation to revise or update any forward-looking statement for any reason.

BALANCE SHEETS

In thousands, except share and per share data

										Convenience
										Translation
	December 31,			March 31,						March 31,
	2020			2020			2021			2021
	Audited			Unaudited						Unaudited
				N I S						U.S. dollars
CURRENT ASSETS:

Cash and cash equivalents		9,421			42,505			48,577			14,570
Other receivables		1,204			1,540			481			144

		10,625			44,045			49,058			14,714
LONG-TERM ASSETS:
Property, plant and equipment		39,607			35,989			39,252			11,773
Right-of-use assets		6,206			6,899			5,978			1,793
Other long-term assets		473			899			436			131

		46,286			43,787			45,666			13,697

		56,911			87,832			94,724			28,411

CURRENT LIABILITIES:
Trade payables		1,868			3,278			2,085			625
Operating lease liabilities		654			684			641			192
Loan from others		60,421			-			62,346			18,700
Other payables		1,246			807			1,640			492

		64,189			4,769			66,712			20,009
LONG-TERM LIABILITIES:
Liability in respect of government grants		-			12,991			-			-
Operating lease liabilities		6,088			6,641			5,978			1,793
Loan from others		-			117,784			-			-
Warrants		-			6,861			-			-
Other payables		1,135			-			1,135			340
Severance pay liability, net		95			90			95			29

		7,318			144,367			7,208			2,162
SHAREHOLDERS' EQUITY:
Ordinary shares of no par value: Authorized: 700,000,000 shares at March 31, 2021 (unaudited) and 600,000,000 at March 31, 2020 (unaudited) and December 31, 2020; Issued and outstanding: 573,285,824 shares at March 31, 2021 (unaudited) 410,213,977 shares at March 31, 2020 (unaudited), and 461,285,824 shares at December 31, 2020			*)-			*)-			*)-			*)-
Share premium		310,197			262,729			353,783			106,114
Accumulated deficit		(324,793	)		(324,033	)		(332,979	)		(99,874	)

		(14,596	)		(61,304	)		20,804			6,240

		56,911			87,832			94,724			28,411

*) Represents less than 1 NIS\USD

STATEMENTS OF COMPREHENSIVE LOSS

In thousands, except share and per share data

										Convenience translation
	Year ended December 31,			Three months ended March 31,						Three months ended March 31,
	2020			2020			2021			2021
	Audited			Unaudited						Unaudited
	NIS									U.S. dollars

Operating expenses:
Research and development, net of participations		51,463			19,068			2,750			825
Marketing, general and administrative		16,687			981			4,005			1,201
Other income		(75,484	)		-			-			-

Total operating expenses (income)		(7,334	)		20,049			6,755			2,026
											-
Operating income (loss)		7,334			(20,049	)		(6,755	)		(2,026	)

Financial income		3,843			16,502			1,182			354
Financial expense		(15,632	)		(148	)		(2,613	)		(784	)

Net loss and total comprehensive loss		(4,455	)		(3,695	)		(8,186	)		(2,456	)
Basic and Diluted net loss per share		(0.01	)		(0.01	)		(0.02	)		(0.005	)

Weighted average number of shares outstanding used to compute basic and diluted loss per share		443,260,878			408,596,752			530,840,391			530,840,391

Exhibit 99.2

BIONDVAX PHARMACEUTICALS LTD.

INTERIM FINANCIAL STATEMENTS

AS OF MARCH 31, 2021

NIS IN THOUSANDS

UNAUDITED

INDEX

	Page

Balance Sheets	F-2 - F-3

Statements of Comprehensive Loss	F-4

Statements of Changes in Shareholders’ Equity (Deficiency)	F-5

Statements of Cash Flows	F-6- F-7

Notes to Interim Financial Statements	F-8 - F-11

- - - - - - - - - - -

F-1

BIONDVAX PHARMACEUTICALS LTD.

BALANCE SHEETS

In thousands, except share and per share data

							Convenience
							Translation
							(Note 2c)
	December 31,		March 31,				March 31,
	2020		2020		2021		2021
	Audited		Unaudited				Unaudited
	N I S						U.S. dollars
CURRENT ASSETS:
Cash and cash equivalents		9,421		42,505		48,577		14,570
Other receivables		1,204		1,540		481		144

		10,625		44,045		49,058		14,714
LONG-TERM ASSETS:
Property, plant and equipment		39,607		35,989		39,252		11,773
Right-of-use assets		6,206		6,899		5,978		1,793
Other long-term assets		473		899		436		131

		46,286		43,787		45,666		13,697

		56,911		87,832		94,724		28,411

The accompanying notes are an integral part of the interim financial statements.

F-2

BIONDVAX PHARMACEUTICALS LTD.

BALANCE SHEETS

In thousands, except share and per share data

										Convenience
										Translation
										(Note 2c)
	December 31,			March 31,						March 31,
	2020			2020			2021			2021
	Audited			Unaudited						Unaudited
	N I S									U.S. dollars
CURRENT LIABILITIES:
Trade payables		1,868			3,278			2,085			625
Operating lease liabilities		654			684			641			192
Loan from others		60,421			-			62,346			18,700
Other payables		1,246			807			1,640			492

		64,189			4,769			66,712			20,009
LONG-TERM LIABILITIES:
Liability in respect of government grants		-			12,991			-			-
Operating lease liabilities		6,088			6,641			5,978			1,793
Loan from others		-			117,784			-			-
Warrants		-			6,861			-			-
Other payables		1,135			-			1,135			340
Severance pay liability, net		95			90			95			29

		7,318			144,367			7,208			2,162
SHAREHOLDERS’ EQUITY:
Ordinary shares of no par value: Authorized: 700,000,000 shares at March 31, 2021 (unaudited) and 600,000,000 at March 31, 2020 (unaudited) and December 31, 2020; Issued and outstanding: 573,285,824 shares at March 31, 2021 (unaudited) 410,213,977 shares at March 31, 2020 (unaudited), and 461,285,824 shares at December 31, 2020		*)	-		*)	-		*)	-		*)	-
Share premium		310,197			262,729			353,783			106,114
Accumulated deficit		(324,793	)		(324,033	)		(332,979	)		(99,874	)

		(14,596	)		(61,304	)		20,804			6,240

		56,911			87,832			94,724			28,411

Represents less than NIS\USD 1.

The accompanying notes are an integral part of the interim financial statements.

June XX, 2021
Date of approval of the	Mark Germain	Amir Reichman	Uri Ben-Or
financial statements	Chairman of the Board	Chief Executive officer	Chief Financial officer

F-3

BIONDVAX PHARMACEUTICALS LTD.

STATEMENTS OF COMPREHENSIVE LOSS

In thousands, except share and per share data

										Convenience translation
	Year ended December 31,			Three months ended March 31,						Three months ended March 31,
	2020			2020			2021			2021
	Audited			Unaudited						Unaudited
	NIS									U.S. dollars

Operating expenses:
Research and development, net of participations		51,463			19,068			2,750			825
Marketing, general and administrative		16,687			981			4,005			1,201
Other income		(75,484	)		-			-			-

Total operating expenses (income)		(7,334	)		20,049			6,755			2,026
											-
Operating income (loss)		7,334			(20,049	)		(6,755	)		(2,026	)

Financial income		3,843			16,502			1,182			354
Financial expense		(15,632	)		(148	)		(2,613	)		(784	)

Net loss and total comprehensive loss		(4,455	)		(3,695	)		(8,186	)		(2,456	)
Basic and Diluted net loss per share		(0.01	)		(0.01	)		(0.02	)		(0.005	)

Weighted average number of shares outstanding used to compute basic and diluted loss per share		443,260,878			408,596,752			530,840,391			530,840,391

The accompanying notes are an integral part of the interim financial statements.

F-4

BIONDVAX PHARMACEUTICALS LTD.

STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (DEFICIENCY)

In thousands, except share and per share data

	Share capital			Share premium		Accumulated deficit			Total Equity (Deficiency)
	Unaudited
	NIS in thousands

Balance as of January 1, 2021		*)	-		310,197		(324,793	)		(14,596	)

Total comprehensive loss		-					(8,186	)		(8,186	)
Issuance of shares, net		-			42,129		-			42,129
Share-based compensation		-			1,457		-			1,457

Balance as of March 31, 2021		*)	-		353,783		(332,979	)		20,804

Balance as of March 31, 2021 (convenience translation into U.S. dollars (see Note 2c)		*)	-		106,114		(99,874	)		6,240

	Share capital			Share premium		Accumulated deficit			Total Deficiency
	Unaudited
	NIS in thousands

Balance as of January 1, 2020		*)	-		255,285		(320,338	)		(66,053	)

Total comprehensive loss		-			-		(3,695	)		(3,695	)
Exercise of warrants		-			7,240		-			7,240
Share-based compensation		-			204		-			204

Balance as of March 31, 2020		*)	-		262,729		(324,033	)		(61,304	)

Balance as of March 31, 2020 (convenience translation into U.S. dollars (see Note 2c)		*)	-		78,803		(97,190	)		(18,387	)

	Share capital			Share premium		Accumulated deficit			Total Deficiency
	Audited
	NIS in thousands

Balance as of January 1, 2020		*)	-		255,285		(320,338	)		(66,053	)

Total comprehensive loss		-			-		(4,455	)		(4,455	)

Exercise of warrants		-			45,274		-			45,274
Exercise of options		-			166		-			166
Share-based compensation		-			9,472		-			9,472

Balance as of December 31, 2020		*)	-		310,197		(324,793	)		(14,596	)

Balance as of December 31, 2020 (convenience translation into U.S. dollars (see Note 2c)		*)	-		93,040		(97,418	)		(4,378	)

Represents less than NIS\USD 1.

The accompanying notes are an integral part of the interim financial statements.

F-5

BIONDVAX PHARMACEUTICALS LTD.

STATEMENTS OF CASH FLOWS

In thousands, except share and per share data

										Convenience translation
	Year ended December 31,			Three months ended March 31,						Three months ended March 31,
	2020			2020			2021			2021
	Audited			Unaudited						Unaudited
	NIS									U.S. dollars

Cash flows from operating activities:
Net loss		(4,455	)		(3,695	)		(8,186	)		(2,456	)

Adjustments to reconcile net loss to net cash used in operating activities:

Adjustments to profit and loss items:
Depreciation of property, plant and equipment and right-of-use assets		2,436			601			605			181
Net financing expenses (income)		12,940			(8,539	)		(991	)		(297	)
Capital gain		(160	)		(160	)		-			-
Increase (decrease) in liability with respect to loans from others		(63,359	)		(5,996	)		1,925			577
Decrease in liability with respect to government grants		(14,812	)		(1,821	)		-			-
Share-based compensation		9,472			204			1,457			437
Change in employee benefit liabilities, net		6			1			-			-
		(53,477	)		(15,710	)		2,996			898
Changes in asset and liability items:
Decrease (increase) in other receivables		(548	)		(884	)		723			217
Decrease in trade payables		(15,194	)		(13,784	)		217			65
Increase (decrease) in short- and long-term other payables		1,178			(396	)		394			118

		(14,564	)		(15,064	)		1,334			400

Cash paid and received during the year for:
Interest paid		(45	)		(12	)		(8	)		(2	)
Interest received		2			-			-			-

		(43	)		(12	)		(8	)		(2	)

Net cash flows used in operating activities		(72,539	)		(34,481	)		(3,864	)		(1,160	)

The accompanying notes are an integral part of the interim financial statements.

F-6

BIONDVAX PHARMACEUTICALS LTD.

STATEMENTS OF CASH FLOWS

In thousands, except share and per share data

										Convenience translation
	Year ended December 31,			Three months ended March 31,						Three months ended March 31,
	2020			2020			2021			2021
	Audited			Unaudited						Unaudited
	NIS									U.S. dollars
	(In thousands)
Cash Flows from Investing Activities:
Purchase of property and equipment		(6,132	)		(1,372	)		(22	)		(7	)
Proceeds from sale of property and equipment		160			160			-			-
Decrease (increase) in other long-term assets		37			(389	)		37			11
											-
Net cash provided by (used in) investing activities		(5,935	)		(1,601	)		15			4

Cash Flows from Financing Activities:

Repayment of operating lease liabilities		(1,240	)		(312	)		(306	)		(92	)
Proceeds from exercise of options to employees		166			-			-			-
Proceeds from exercise of warrants to public		14,790			4,446			-			-
Proceeds from issuance of shares, net of issuance costs		-			-			42,129			12,636

Net cash provided by financing activities		13,716			4,134			41,823			12,544

Exchange differences on balances of cash and cash equivalents		1,712			1,987			1,182			356

Decrease in cash and cash equivalents		(63,046	)		(29,961	)		39,156			11,744
Balance of cash and cash equivalents at the beginning of the period		72,467			72,467			9,421			2,826

Balance of cash and cash equivalents at the end of the period		9,421			42,506			48,577			14,750

Non-cash activities:

Exercise of warrants to public		30,484			-			-			-

The accompanying notes are an integral part of the interim financial statements.

F-7

BIONDVAX PHARMACEUTICALS LTD.

NOTES TO INTERIM FINANCIAL STATEMENTS

In thousands, except share and per share data

NOTE 1: GENERAL

BiondVax Pharmaceuticals Ltd. (“the Company”) is focused on developing and ultimately commercializing products for prevention and treatment of infectious diseases and related illnesses. The Company was incorporated on July 21, 2003 in Israel, and started its activity on March 31, 2005. The Company’s principal executive offices and main laboratory are located at Jerusalem BioPark, 2nd floor, Hadassah Ein Kerem Campus, Jerusalem, Israel, next to Hadassah University Hospitals and Hebrew University’s Medical School.

On May 15, 2015, the Company completed a public offering of securities in the United States.

On March 28, 2017, the Company received an approval from the Investment Center of the Ministry of Economy and Industry of the State of Israel, for a grant (“the Grant”) representing 20% of a NIS 20,000 budget to be utilized towards the construction of a factory for the production of Phase 3 and commercial batches of the Company’s product. The receipt of the Grant was subject to certain terms and conditions, including those outlined under the Israeli Encouragement of Capital Investment Law,1959. The terms and conditions included, inter alia, the following: (a) at least 24% of the investments in the planned manufacturing facility’s fixed assets would be financed by additional share capital; (b) the Company would maintain its intellectual property and manufacturing facility in Israel for a period of at least 10 years.

To the report date the Investment Center of the Ministry of Economy and Industry of the State of Israel has yet to approve the grant to the company.

On June 19, 2017, the Company entered into a Finance Contract with the European Investment bank (EIB) for a total amount of € 20,000 (approximately $ 23,200) and up to 50% of the Company’s expected cost of developing and marketing the Company’s product candidate, M-001. In addition, as repayment features, EIB was entitled to receive the higher between 3% of any M-001 sales revenues for a period of ten years, or realizing a cash-on-cash multiple of 2.8 times.

On April 22, 2019, the EIB agreed to expand the 2017 financing agreement to the Company by an additional € 4,000 to a total of € 24,000 (approximately $ 27,600).

On October 23, 2020, the Company announced Phase 3 clinical trial results of its M-001 universal vaccine product. The results did not demonstrate a statistically significant difference between the vaccinated group and the placebo group in reduction of flu illness and severity. Therefore, the study failed to meet both the primary and secondary efficacy endpoints. However, the study’s primary safety endpoint was met.

On January 26, 2021, the EIB notified us, among other things, that they will not consider the failure of our pivotal phase 3 trial for M-001 to meet the primary and secondary efficacy endpoints as a trigger for prepayment of the loan extended under the Finance Contract. However, the EIB cautioned us that their letter is not a consent, agreement, amendment or waiver in respect of the terms of the Finance Contract, reserving any other right or remedy the EIB may have now or subsequently. There is no guarantee that the decision by the EIB in their letter will not change at any time and without any notice or that the EIB will not determine that an event of default has occurred under the Finance Contract, which could result in all loans extended under the Finance Contract being accelerated and secured creditor remedies being exercised. If some or all of the loans under the Finance Contract are accelerated by the EIB, or secured creditor remedies are exercised, we expect such events to adversely impact our ability to continue as a going concern.

F-8

BIONDVAX PHARMACEUTICALS LTD.

NOTES TO INTERIM FINANCIAL STATEMENTS

In thousands, except share and per share data

NOTE 1: GENERAL (Cont.)

On January 21, 2021, the Company announced the appointment of Amir Reichman as its new Chief Executive Officer. Mr. Reichman and Dr. Ron Babecoff, its founder and former CEO, shared duties during a transition period while Mr. Reichman completed his former work obligations. Effective March 2, 2021, Mr. Reichman assumed the CEO position full time and Dr. Babecoff continued as Senior Advisor to the Company.

On February 2, 2021, the Company closed an underwritten offering in which it sold 2,434,783 ADSs at a public offering price of $4.95 per ADS. On February 10, 2021, Aegis Capital Corp., the sole bookrunning manager for the underwritten offering, fully exercised its over-allotment option to purchase an additional 365,217 ADSs, bringing total gross proceeds to the Company from the offering including exercise of the over-allotment option of approximately $13,800. The Company received a net sum of $12,750 (approximately NIS 42,129).

In the three months ended March 31, 2021, the Company incurred a loss of NIS 8,186 ($ 2,456) and negative cash flows from operating activities of NIS 3,864 ($ 1,160) and it has an accumulated deficit of NIS 332,979 ($ 99,874) as of that date.

To date the Company has not generated any revenues and will need additional funds to finance its operations in the future.

Furthermore, the Company intends to continue to finance its operating activities by raising capital. There are no assurances that the Company will be successful in obtaining an adequate level of financing needed for its long-term research, development and potential commercialization activities.

If the Company will not have the sufficient liquidity resources, the Company may not be able to continue the development of its prospective products or may be required to implement a cost reduction and may be required to delay part of its development program. The Company’s management and Board of Directors are of the opinion that its current financial resources will be sufficient to continue the operations of the Company for at least the next twelve months.

F-9

BIONDVAX PHARMACEUTICALS LTD.

NOTES TO INTERIM FINANCIAL STATEMENTS

In thousands, except share and per share data

NOTE 2:- CONVENIENCE TRANSLATION INTO U.S. DOLLARS

The financial statements as of March 31, 2021 and for the three months then ended have been translated into dollars using the representative exchange rate as of that date ($ 1 = NIS 3.334). The translation was made solely for the convenience of the reader. The amounts presented in these financial statements should not be construed to represent amounts receivable or payable in dollars or convertible into dollars, unless otherwise indicated in these statements.

NOTE 3: SIGNIFICANT ACCOUNTING POLICIES

These financial statements have been prepared in a condensed format as of March 31, 2021, and for the three months then ended (“interim financial statements”). These financial statements should be read in conjunction with the Company’s annual financial statements as of December 31, 2020, and for the year then ended and accompanying notes (“annual financial statements”).

Basis of preparation of the interim financial statements

The interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles for the preparation of financial statements for interim periods, as prescribed in IAS 34, “Interim Financial Reporting”, and in accordance with the disclosure requirements of Chapter D of the Securities Regulations (Periodic and Immediate Reports), 1970.

The significant accounting policies and methods of computation adopted in the preparation of the interim financial statements are consistent with those followed in the preparation of the Company’s annual financial statements.

NOTE 4: SUBSEQUENT EVENTS

On April 6, 2021, the Company held an Extraordinary Meeting of Shareholders (the “Meeting”). At the Meeting, among other approved resolutions, the Company approved grants to the board members and CEO:

30,000 RSUs to 6 directors, to vest in equal monthly installments during a period of three (3) years (if they continue to serve as directors) commencing one (1) month following the date of shareholder approval and would become fully vested, in accordance with the terms of the grant, on April 6, 2024. The RSUs would be subject to accelerated vesting in the event of a change of control.

Options to purchase 150,000 ADSs of the Company at an exercise price of the greater of (i) $6.95, which is the greater of (x) 130% of the average closing price on Nasdaq during the 30 trading days prior to board approval and (y) 130% of the weighted average closing price on Nasdaq during the 30 calendar days prior to board approval), and (ii) 100% of the weighted average closing price on Nasdaq in the 30 calendar days prior to shareholder approval. The options, which would include the ability to exercise on a cashless basis, would vest in equal monthly installments during a period of three (3) years commencing one (1) month following the date of shareholder approval and would become fully vested, in accordance with the terms of the grant, on April 6, 2024. The options would be subject to accelerated vesting and would become immediately exercisable in the event of a change of control. In addition, the options would have a term of ten (10) years following the date of shareholder approval and, to the extent the options are vested, such vested options would continue to be exercisable during such term in the event of termination of service to the Company without cause.

F-10

BIONDVAX PHARMACEUTICALS LTD.

NOTES TO INTERIM FINANCIAL STATEMENTS

In thousands, except share and per share data

NOTE 4: SUBSEQUENT EVENTS (Cont.)

An amendment to the Company’s Articles of Association increasing the registered share capital of the Company by an additional 1,100,000,000 Ordinary Shares (the equivalent of 27.5 million ADSs) such that the total registered share capital of the Company would consist of 1,800,000,000 Ordinary Shares, no par value (the equivalent of 45 million ADSs).

On April 6, 2021, the Company’s shareholders approved the issuance to Mr. Amir Reichman, the Company’s new CEO, 600,000 restricted share units (the “RSUs”) under the Company’s 2018 Israeli Share Option Plan, which vest over a period of five years, 20% to vest each year on the anniversary date of the commencement date and would become fully vested, in accordance with the terms of the grant, on March 2, 2026. The ADSs underlying the RSUs may not be sold by Mr. Reichman during the term of his employment except that, commencing on March 2, 2024, sales may be made pursuant to a Rule 10b5-1 plan, with the number of RSUs sold during any one year period not exceeding five percent of the vested RSUs held by Mr. Reichman at the time of such sales.

- - - - - - - - - - -

F-11